Shenzhen GeneMind Biosciences Co., Ltd. (GeneMind Biosciences Co., Ltd., hereinafter referred to as ‘GeneMind’) was founded in 2012 and is headquartered in Luohu, Shenzhen. Its facility includes more than 8,000 square meters‘ of research and development laboratories and GMP production lines.
From the company’s inception, GeneMind aims at the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostic platform. GeneMind is committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions. GeneMind has launched high-throughput sequencing platform GenoLab M, FASTASeq 300 and SURFSeq 5000 which can provide ‘instrument-reagent-flow cell-software’ full-platform solutions. With nearly 300 technical patents, covering mainland China , Hong Kong, Europe, and the United States, GeneMind is one of the few companies in the world that possess the core DNA sequencing technology and independent products.
After several years of hard work, GeneMind has mastered the key DNA sequencing technology, and realized production of core materials such as enzymes, nucleic acids, dyes, and biochips in China, providing research and medical institutions with Chinese gene sequencing solutions for all over the world.
Explore life's mystery for better healthcare
Everyone’s genome is composed of more than 3,000,000,000 DNA bases, with the mysteries of life and health inside. GeneMind Bioscience strives to decode the mystery of life to improve human health.
Become a world-class enterprise in the field of life science and healthcare
Keep our eyes on the stars, and our feet on the ground.
Communicate directly and frankly
Innovate with rigorous work
Study now and forever
Cooperate in interdisciplinary
Chairman and CEO
- Doctor of Engineering, University of Science and Technology of China
- Shenzhen high level professionals. Experts employed by Shenzhen standard expert database. Director of Guangdong single molecule sequencer and reagent engineering research technology center
- More than 10 years of entrepreneurial management experience in high-tech enterprises
- Master of Polymer Chemistry, Case Western Reserve University, USA
- More than 20 years of experience in the Silicon Valley genetic industry in the United States
- Former chief scientist and senior director of Pacific Biosciences, USA. Research and development of chip, chemistry and system integration. Participate in the advent of pacbio’s third generation gene sequencer
- Director of nanoparticle program at Intel Research Institute. Senior scientist at GE Healthcare
- PhD in Computational Optics, University of Science and Technology of China and Chinese Academy of Sciences(joint training)
- High-level talents in Luohu District, Shenzhen
- More than 10 years R & D management experience. Optical expert in biomedical and aerospace fields. The principal of national 863 project and National Natural Science Foundation of China
VP, Engineering & Manufacturing
- Master of Engineering, Harbin Institute of Technology
- Former Mindray medical device Expert
- More than 10 years of experience in IVD medical device development
- Master of Finance, MBA, University of Houston, USA
- Worked in the largest central enterprise finance company in China.Gained many years of experience in the capital market of securities firms and investment banks
Academician of CAS / Member of the International Eurasian Academy of Sciences / Bioinformatician / Researcher, Institute of Biophysics, Chinese Academy of Sciences
Dr. Chen, one of the earliest scientific researchers engaged in theoretical biology and bioinformatics research in my country, has been conducting systematic research in the field of bioinformatics. He has participated in the first complete genome sequence assembly and gene identification in China. He researched and established a draft of the human genome and rice genome work undertaken by cryptographic methods in China. His series of achievements in the field of non-coding genes and biological network research has made important and innovative contributions to international research in bioinformatics and related fields.
Genome scientist / Researcher, Beijing Institute of genomics, Chinese Academy of Sciences / Former Co-Founder of BGI / National Outstanding Youth
Professor Yu is a world-renowned expert in genomics, bioinformatics, and human genetics. He has participated in and presided over major scientific research projects such as the International Human Genome Project. He has published more than 100 scientific papers and more than 20 scientific monographs in major international journals such as Nature and Science. These publications have made significant contributions to the practice of large-scale DNA sequencing. In 2002, he was selected as the first time annual global research leader by Scientific American magazine.
Gene sequencing scientist / Professor of Southeast University / Director of State Key Laboratory of Bioelectronics / Changjiang Scholar / National outstanding youth
Professor Lu has made a number of research results in the new generation of high-throughput DNA sequencing technology, new biochips and their applications, and bioinformatics analysis. He designed and developed a new generation of experimental prototypes and sequencing chips for high-throughput DNA sequencing, and applied them to clinical sample testing. He has made significant contributions to the research and development of high-throughput gene sequencers in China.
February – Published a special article on our single molecule sequencing technology in Nature Biotechnology.
April-Successfully developed Genocare alpha prototype, the first engineering prototype of single molecule sequencer.
December-Released the sequencing data of biological samples based on Genocare single- molecule sequencing platform for the first time.
June-Successfully developed the product prototype of GenoCare single-molecule sequencer.
October-Completed the first domestic preclinical study of NIPT based on single molecule sequencing technology in combination with the Obstetrics and Gynecology Hospital of Zhejiang University School of Medicine and other units.
April-Obtained more than 200 million CNY A round financing jointly participated by several institutions. Start the construction of single molecule gene sequencer and supporting reagent production line, and the application of medical device license.
September – GeneMind Biosciences’ R&D and production base officially settled in Luohu District, with a total work area of more than 8,000 square meters, including over 3,000 square meters of sequencer and kit GMP production lines.
February-GenoCare 1600 single-molecule sequencer successfully passed the medical device registration test.
August-GenmaiCare 1600 officially launched clinical trials of class III medical devices.
December-GenoCare single-molecule gene sequencer, NIPT, PGT-A test kits and other five products received the EU CE certification.
January-GeneMind Biosciences completed tens of millions of A+ round financing, accelerating the promotion of single-molecule gene sequencing platform applications.
May-GeneMind Biosciences’new coronavirus SARS-CoV-2 nucleic acid detection kit based on fluorescent PCR and single-molecule fluorescent sequencing has been successively approved by the European Union CE certification.
September-Completed 140 million of B-round financing. Expanded sequencing applications.
October-Genemind released new sequencing platform – GenoLab in special product launch event.
June – Approved as the first provincial-level “academician workstation” in the field of gene sequencers in China.
September – Completed a B+round financing of RMB 410 million.
October – The production base of the GenoLab M series high-throughput gene sequencer was officially put into operation, further improving the overall production and delivery capacity and speed.
November – Following the approval to establish the Guangdong Provincial Academician Workstation, it was awarded the license of the Shenzhen Municipal Academician (Expert) Workstation and became a gene sequencer enterprise with provincial and municipal level academician workstations.
July – The single molecule gene sequencing platform GenoCare 1600 has been approved for clinical application by the National Drug Administration (NMPA) of China, becoming the world’s first single molecule gene sequencer approved for clinical diagnosis by NMPA;
November – The newly developed gene sequencing platform FASTASeq 300 will be released, forming a high/medium/low flux coverage and layout of sequencing equipment from scientific research to clinical use.